Latest News and Press Releases

Positive data from the ROSALIE Phase 1/2 trial presented at 2023 SNO Annual Meeting Median survival of 14.5 months and 18-months survival rate of 43.1% in a 26-patient cohort where EO2401 was...

PARIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its...

Immune-monitoring data from the ongoing trials of EO2401 in adrenal tumors (SPENCER) and in recurrent glioblastoma (ROSALIE) High degree of homology with TAAs and robust immune responses validate the...

LLS TAP is a strategic funding initiative to accelerate innovative blood cancer therapeutics Strategic equity investment of €3 million to support clinical advancement of EO2463 in Non-Hodgkin’s...

PARIS, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on...

Updated results demonstrate sustained efficacy with a good safety profile Degree of tumor shrinkage on CT scans correlates with strength of CD8+ T cell specific immune response against EO2401...

PARIS, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its...

First clinical trial of an OncoMimics™ immunotherapy to use liquid biopsy monitoring to measure ctDNA clearance as an indicator of treatment efficacy EO2040 is Enterome’s fourth OncoMimics™...

EO4010 uniquely mimics five distinct tumor-associated antigens designed to provide multi-targeted, broad tumor coverage, maximizing tumor killing and preventing immune escape Paris, France – June 30,...

EO2463 uniquely targets four distinct B cell markers to maximize tumor killing and prevent immune escape, generating fast, strong and durable CD8+ T cell activation against malignant B cells ...